Kelly Dooley, MD, MPH, PhD, is an infectious diseases physician and clinical pharmacologist. She is Director of the Division of Infectious Diseases at Vanderbilt University Medical Center, where she serves as the Addison B. Scoville Jr. Professor of Medicine and Professor of Pathology, Microbiology, and Immunology. Her clinical work centers on comprehensive infectious diseases care, antimicrobial and anti-infective pharmacotherapy, and maternal and pediatric infectious diseases. Her research focuses on anti-infective therapeutics and pharmacology, the design and leadership of multicenter clinical trials, and treatment optimization for priority and vulnerable populations in global health settings. Her specific focus is on tuberculosis therapeutics and TB-HIV co-treatment. Dooley’s leadership includes advising the World Health Organization on anti-infective therapeutics, specifically TB and HIV, and serving on the Board of Directors of the American Society for Clinical Pharmacology and Therapeutics, as well as participation on major international scientific committees. She has been recognized with a NIAID NIH MERIT Award and the Treatment Action Group’s Research in Action Award. She earned her MD from Duke University School of Medicine, completed an MPH in Epidemiology at the University of North Carolina at Chapel Hill and a PhD in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health, and trained at Johns Hopkins University in Internal Medicine residency followed by fellowships in Infectious Diseases and Clinical Pharmacology.
Division Chief, Infectious Diseases
2022 – present
Medical School
1995 – 1999
Residency
1999 – 2002
Fellowship
2005 – 2008